CytoDyn Inc (NASDAQ:CYDY) has been given a $2.00 target price by investment analysts at HC Wainwright in a report issued on Thursday. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 179.04% from the stock’s current price.
Separately, Zacks Investment Research upgraded CytoDyn from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th.
CytoDyn (NASDAQ:CYDY) opened at 0.71675 on Thursday. The company’s market cap is $109.49 million. CytoDyn has a 1-year low of $0.46 and a 1-year high of $1.17. The stock has a 50 day moving average price of $0.73 and a 200 day moving average price of $0.66.
CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.
Receive News & Ratings for CytoDyn Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc and related companies with MarketBeat.com's FREE daily email newsletter.